Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Alan Kivitz; Xenofon Baraliakos; Elena Tomaselli Muensterman; Arthur Kavanaugh; Désirée van der Heijde; Piotr Adrian Klimiuk; Guillermo Valenzuela; Eva Dokoupilová; Gabrielle Poirier; Bhaskar Srivastava; Sue Dasen; X. Zhang; Ting Hong; Jingjing Chen; Peter Pothula; Haoling H. Weng; Mona Trivedi; Apinya Lertratanakul

doi:10.1016/j.ard.2025.05.023

Key Points

To evaluate the efficacy and safety profile of the selective tyrosine kinase 2 inhibitor zasocitinib (TAK-279) in patients with active psoriatic arthritis.
Conducted a randomized phase 2b trial assessing oral zasocitinib at doses of 15 mg and 30 mg.
Evaluated therapeutic responses across core disease domains alongside safety and tolerability monitoring.
Zasocitinib at both 15 mg and 30 mg demonstrated efficacy across core disease domains in active psoriatic arthritis.
No new safety signals were observed across the evaluated dose cohorts.

Implication

Randomized trial demonstrates core domain efficacy of zasocitinib in active psoriatic arthritis, highlighting its therapeutic potential.

Abstract

Here, 30 mg and 15 mg zasocitinib demonstrated efficacy across core domains in patients with active PsA with no new safety signals. These findings will be confirmed in ongoing larger studies of longer duration.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kivitz et al. (2025) studied this question.

synapsesocial.com/papers/69d850c0f4e559c61eae36d8 https://doi.org/10.1016/j.ard.2025.05.023

View Full Paper

Ask AI

Bookmark

Share

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Key Points

Implication

Abstract

Discussion

Cite This Study

Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading